NCT03563053: A trial that was reported late by Quince Therapeutics S.p.A.
This trial has reported, although it was 235 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03563053 |
|---|---|
| Title | Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients With Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 12, 2018 |
| Completion date | Sept. 2, 2022 |
| Required reporting date | Sept. 2, 2023, midnight |
| Actual reporting date | April 24, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 235 |